Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 205 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: levonorgestrel Clear all

Conditions: IUD, IUD Insertion Complication, IUD; Complications
Interventions: Sound sparing levonorgestrel 52 mg IUD placement; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Healthy Women, Female Contraception
Interventions: levonorgestrel butanoate (LB) injection; Biological
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Davis, California • Denver, Colorado • Boston, Massachusetts + 4 more

Conditions: Contraception
Interventions: Emergency contraception website, Emergency contraception video; Other
Lead sponsor: Planned Parenthood League of Massachusetts; Other
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Contraception
Interventions: Copper IUD, Levonorgestrel IUD; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: Logan, Utah • Ogden, Utah • Orem, Utah + 3 more

Conditions: Contraceptive Usage
Interventions: levonorgestrel butanoate; Biological
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Drug Interactions
Interventions: BIIB074, OC (ethinyl estradiol and levonorgestrel); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Postpartum
Interventions: Offer of Participant's Choice of Contraception Method; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 15 Years to 35 Years · Female only
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteer
Interventions: Ethinyl Estradiol + Levonorgestrel, ABBV-722; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Contraception
Interventions: AG200-15, Levora; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more

Conditions: Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions: Tamoxifen, Placebo (for Tamoxifen); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Inflammatory Bowel Diseases, Contraception, Menstrual Problem
Interventions: Proposed study design and randomization scenarios, Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments, Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Participants
Interventions: Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG]); Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: HIV
Interventions: no intervention; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 294 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Coronary Heart Disease
Interventions: Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: IUD, Contraceptive Implant, Contraception, Birth Control, Emergency Contraception
Interventions: Copper T-380 IUD, LNG IUD, Contraceptive implant Nexplanon, Depo-Provera; Drug · Device
Lead sponsor: University of Utah; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: West Valley City, Utah

Conditions: Contraception
Interventions: Levonorgestrel IUD, copper IUD, etonorgestrel implant; Device
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 15 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Breakthrough Bleeding
Interventions: DR-1031, Seasonale®, Portia®; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more

Conditions: Menstruation Disturbances, Premenstrual Syndrome
Interventions: levonorgestrel/ethinyl estradiol; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 69
States / cities: Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more

Conditions: Intrauterine Device Expulsion, Medical Abortion, Induced Abortion
Interventions: IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]; Device
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Boston, Massachusetts • Salt Lake City, Utah

Conditions: Blood Coagulation Disorders
Interventions: Levonorgestrel-containing IUD (Mirena®), Copper-containing IUD (Paraguard®); Device
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Healthy Participants
Interventions: Povorcitinib, Levonorgestrel/Ethinyl estradiol; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Epilepsy, Contraception
Interventions: levonorgestrel IUS; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV, Immune Cells (Mucosal and Systemic), Contraception
Interventions: levonorgestrel exposure, DMPA exposure, etonogestrel exposure, IUD insertion, subdermal contraceptive implant insertion; Drug · Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 326 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pregnancy Prevention
Interventions: Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram; Drug · Other
Lead sponsor: InnovaGyn, Inc.; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Search by objective public record fields.

IUD Placement Without Sounding

A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception

Targeted Video Messaging About Emergency Contraception

RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for EC

A Phase I Study to Evaluate the PK and PD of a Single Injection of Levonorgestrel Butanoate for Female Contraception

A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen

Home-based Delivery of the Contraceptive Implant in Postpartum Guatemalan Women

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

Hormonal Influences on Inflammatory Bowel Diseases

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception

Relationship Between the Menstrual Cycle and Heart Disease in Women

Quick Start of Highly Effective Contraception

Patient Compliance With Long-Acting Reversible Contraception Administration

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

Insertion of an Intrauterine Device (IUD) After Medical Abortion

The Effect of a Levonorgestrel-releasing Intrauterine Device (IUD) Versus a Copper Containing IUD on Risk of Blood Clots

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users

Quantification of Immune Cells in Women Using Contraception (CHIC II)

Phase II Study of Ovulation in Obese Women